Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06875934 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 14, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Active, Not Recruiting Enrollment target: estimated 140 to confirmed 145 · Start date changed from estimate of Mar 2025 to Mar 28, 2025 · Site contact updatedv2 Show 3 more changesShow less
    • Enrollment target: estimated 140 to confirmed 145
    • Start date changed from estimate of Mar 2025 to Mar 28, 2025
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 injection in patients with moderate to severe plaque psoriasis.
Trial Details
NCT Number NCT06875934
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Moderate to Severe Plaque Psoriasis
Enrollment 145 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov